9-OH risperidone response in risperidone poor responders: An open study of drug response concordance

Roberto Cavallaro, Marta Bosia, Carmelo Guglielmino, Enrico Smeraldi

Research output: Contribution to journalArticle

Abstract

A major topic about the pharmacotherapy of schizophrenia is the wide variability of antipsychotic effects among patients when treated with each drug, leading to the clinical judgement of a limited 'class effect', also for similar molecules. Paliperidone is the major metabolite of risperidone and pharmacodynamic activities are highly comparable, even though some differences have been reported. Paliperidone showed to be effective in the treatment of schizophrenia in a number of short and long term studies, however only two short term studies evaluated the differences in clinical response among patients switched from risperidone to paliperidone. The aim of this study is to evaluate, by means of a naturalistic observational follow-up, the possible concordance of clinical response to risperidone and paliperidone. Thirty-one patients affected by schizophrenia treated with risperidone and showing poor clinical response were enrolled in the study. Patients were switched to paliperidone and assessed for psychopathology, cognition, general functioning, extrapyramidal tolerability and attitude towards treatment at baseline and after 2, 6 and 12 weeks of treatment. The repeated measures analysis showed an overall significant improvement on several domains after 12 weeks of treatment (Table 1). Remarkably over 40% of patients showed a non-concordant clinical response to paliperidone and risperidone. In conclusion, this naturalistic observation suggests that paliperidone and his mother drug, risperidone may show significant differences both in efficacy and tolerability at individual level. Reasons for this should be looked for at biological levels not necessarily involving the receptor affinity and pharmacological activity profile.

Original languageEnglish
Pages (from-to)109-113
Number of pages5
JournalNeurology Psychiatry and Brain Research
Volume18
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Risperidone
Pharmaceutical Preparations
Schizophrenia
Therapeutics
Paliperidone Palmitate
Psychopathology
Cognition
Antipsychotic Agents
Mothers
Observation
Pharmacology
Drug Therapy

Keywords

  • Paliperidone
  • Psychopharmacology
  • Risperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology
  • Neuroscience(all)

Cite this

9-OH risperidone response in risperidone poor responders : An open study of drug response concordance. / Cavallaro, Roberto; Bosia, Marta; Guglielmino, Carmelo; Smeraldi, Enrico.

In: Neurology Psychiatry and Brain Research, Vol. 18, No. 3, 06.2012, p. 109-113.

Research output: Contribution to journalArticle

@article{fb7fa3912f364463bf1077931c4dd342,
title = "9-OH risperidone response in risperidone poor responders: An open study of drug response concordance",
abstract = "A major topic about the pharmacotherapy of schizophrenia is the wide variability of antipsychotic effects among patients when treated with each drug, leading to the clinical judgement of a limited 'class effect', also for similar molecules. Paliperidone is the major metabolite of risperidone and pharmacodynamic activities are highly comparable, even though some differences have been reported. Paliperidone showed to be effective in the treatment of schizophrenia in a number of short and long term studies, however only two short term studies evaluated the differences in clinical response among patients switched from risperidone to paliperidone. The aim of this study is to evaluate, by means of a naturalistic observational follow-up, the possible concordance of clinical response to risperidone and paliperidone. Thirty-one patients affected by schizophrenia treated with risperidone and showing poor clinical response were enrolled in the study. Patients were switched to paliperidone and assessed for psychopathology, cognition, general functioning, extrapyramidal tolerability and attitude towards treatment at baseline and after 2, 6 and 12 weeks of treatment. The repeated measures analysis showed an overall significant improvement on several domains after 12 weeks of treatment (Table 1). Remarkably over 40{\%} of patients showed a non-concordant clinical response to paliperidone and risperidone. In conclusion, this naturalistic observation suggests that paliperidone and his mother drug, risperidone may show significant differences both in efficacy and tolerability at individual level. Reasons for this should be looked for at biological levels not necessarily involving the receptor affinity and pharmacological activity profile.",
keywords = "Paliperidone, Psychopharmacology, Risperidone, Schizophrenia",
author = "Roberto Cavallaro and Marta Bosia and Carmelo Guglielmino and Enrico Smeraldi",
year = "2012",
month = "6",
doi = "10.1016/j.npbr.2012.01.001",
language = "English",
volume = "18",
pages = "109--113",
journal = "Neurology Psychiatry and Brain Research",
issn = "0941-9500",
publisher = "Elsevier GmbH",
number = "3",

}

TY - JOUR

T1 - 9-OH risperidone response in risperidone poor responders

T2 - An open study of drug response concordance

AU - Cavallaro, Roberto

AU - Bosia, Marta

AU - Guglielmino, Carmelo

AU - Smeraldi, Enrico

PY - 2012/6

Y1 - 2012/6

N2 - A major topic about the pharmacotherapy of schizophrenia is the wide variability of antipsychotic effects among patients when treated with each drug, leading to the clinical judgement of a limited 'class effect', also for similar molecules. Paliperidone is the major metabolite of risperidone and pharmacodynamic activities are highly comparable, even though some differences have been reported. Paliperidone showed to be effective in the treatment of schizophrenia in a number of short and long term studies, however only two short term studies evaluated the differences in clinical response among patients switched from risperidone to paliperidone. The aim of this study is to evaluate, by means of a naturalistic observational follow-up, the possible concordance of clinical response to risperidone and paliperidone. Thirty-one patients affected by schizophrenia treated with risperidone and showing poor clinical response were enrolled in the study. Patients were switched to paliperidone and assessed for psychopathology, cognition, general functioning, extrapyramidal tolerability and attitude towards treatment at baseline and after 2, 6 and 12 weeks of treatment. The repeated measures analysis showed an overall significant improvement on several domains after 12 weeks of treatment (Table 1). Remarkably over 40% of patients showed a non-concordant clinical response to paliperidone and risperidone. In conclusion, this naturalistic observation suggests that paliperidone and his mother drug, risperidone may show significant differences both in efficacy and tolerability at individual level. Reasons for this should be looked for at biological levels not necessarily involving the receptor affinity and pharmacological activity profile.

AB - A major topic about the pharmacotherapy of schizophrenia is the wide variability of antipsychotic effects among patients when treated with each drug, leading to the clinical judgement of a limited 'class effect', also for similar molecules. Paliperidone is the major metabolite of risperidone and pharmacodynamic activities are highly comparable, even though some differences have been reported. Paliperidone showed to be effective in the treatment of schizophrenia in a number of short and long term studies, however only two short term studies evaluated the differences in clinical response among patients switched from risperidone to paliperidone. The aim of this study is to evaluate, by means of a naturalistic observational follow-up, the possible concordance of clinical response to risperidone and paliperidone. Thirty-one patients affected by schizophrenia treated with risperidone and showing poor clinical response were enrolled in the study. Patients were switched to paliperidone and assessed for psychopathology, cognition, general functioning, extrapyramidal tolerability and attitude towards treatment at baseline and after 2, 6 and 12 weeks of treatment. The repeated measures analysis showed an overall significant improvement on several domains after 12 weeks of treatment (Table 1). Remarkably over 40% of patients showed a non-concordant clinical response to paliperidone and risperidone. In conclusion, this naturalistic observation suggests that paliperidone and his mother drug, risperidone may show significant differences both in efficacy and tolerability at individual level. Reasons for this should be looked for at biological levels not necessarily involving the receptor affinity and pharmacological activity profile.

KW - Paliperidone

KW - Psychopharmacology

KW - Risperidone

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84862003501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862003501&partnerID=8YFLogxK

U2 - 10.1016/j.npbr.2012.01.001

DO - 10.1016/j.npbr.2012.01.001

M3 - Article

AN - SCOPUS:84862003501

VL - 18

SP - 109

EP - 113

JO - Neurology Psychiatry and Brain Research

JF - Neurology Psychiatry and Brain Research

SN - 0941-9500

IS - 3

ER -